P & G Health Ltd

Why is Procter & Gamble Health Ltd falling/rising?

As of 15-Jun, Procter & Gamble Health Ltd's stock price is at 6,236.80, down 0.59%. Despite this recent decline, the stock has shown positive trends over various time frames and maintains strong financial health, though reduced investor participation may be affecting its price movement.

As of 15-Jun, Procter & Gamble Health Ltd's stock price is currently at 6,236.80, reflecting a decrease of 36.75 points, or 0.59%. Despite this decline, the stock has shown positive performance over various time frames, including a 1-week increase of 0.58% and a notable 17.97% rise over the past month. Year-to-date, the stock has gained 9.40%, contrasting with the Sensex, which has fallen by 10.51% during the same period.<BR><BR>The stock's current performance is described as inline with the sector, and it is trading above its moving averages across multiple time frames, indicating a generally positive trend. However, there is a concerning drop in investor participation, as evidenced by a 28.33% decrease in delivery volume compared to the 5-day average. This decline in trading activity could be contributing to the recent price drop.<BR><BR>On a positive note, the company boasts a high dividend yield of 3.26% and is net-debt free, which are attractive factors for investors. Additionally, the company has demonstrated high management efficiency with a return on equity (ROE) of 36.14% and strong financial results in March, including the highest recorded return on capital employed (ROCE) at 65.27%. <BR><BR>In summary, while Procter & Gamble Health Ltd has experienced a slight decline in its stock price recently, its overall performance metrics and financial health suggest a resilient position in the market, albeit with reduced investor engagement impacting the current price movement.

Which are the latest news on P & G Health Ltd?

How big is P & G Health Ltd?

As of 10th June, Procter & Gamble Health Ltd has a market capitalization of 10,343.00 Cr and reported net sales of 1,407.97 Cr and net profit of 326.91 Cr over the latest four quarters.

As of 10th June, <BR><BR>Market Cap: Procter & Gamble Health Ltd has a market capitalization of 10,343.00 Cr and is classified as a Small Cap company.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 1,407.97 Cr, while the sum of Net Profit for the same period is 326.91 Cr.<BR><BR>Balance Sheet Snapshot: The reporting period for the balance sheet is March 2025. Shareholder's Funds are valued at 536.96 Cr, and Total Assets amount to 759.14 Cr.

Who are in the management team of P & G Health Ltd?

The management team of P & G Health Ltd includes S N Talwar (Chairman), Milind Thatte (Managing Director), Amit Gupta (CFO), and several directors, including independent and non-executive members, overseeing the company's operations and strategy.

The management team of P & G Health Ltd includes the following individuals:<BR><BR>1. **S N Talwar** - Chairman & Independent Director<BR>2. **Rani A Jadhav** - Independent Director<BR>3. **Milind Thatte** - Managing Director<BR>4. **Amit Gupta** - Director (Finance) & CFO<BR>5. **Aalok Agrawal** - Director<BR>6. **Zeal Shah** - Company Secretary & Compliance Officer<BR>7. **Elizabeth Desmond** - Director<BR>8. **S Madhavan** - Independent Director<BR>9. **Lokesh Chandak** - Executive Director<BR>10. **Seema Sambasivan** - Non-Executive Director<BR><BR>This team is responsible for overseeing the company's operations and strategic direction.

Who are the peers of the P & G Health Ltd?

P & G Health Ltd's peers include Marksans Pharma, Viyash Scientifi, Shilpa Medicare, Sanofi Consumer, Akums Drugs, Strides Pharma, Blue Jet Health, and Supriya Lifesci. Key insights show excellent management risk for P & G Health Ltd and peers like Marksans Pharma and Sanofi, with Viyash Scientifi leading in 1-year returns at 26.25%, while P & G Health Ltd has a 1-year return of 6.33%.

Peers: The peers of P & G Health Ltd are Marksans Pharma, Viyash Scientifi, Shilpa Medicare, Sanofi Consumer, Akums Drugs, Strides Pharma, Blue Jet Health, and Supriya Lifesci.<BR><BR>Quality Snapshot: Excellent management risk is observed at Marksans Pharma, Sanofi Consumer, and P & G Health Ltd, while Average management risk is found at Viyash Scientifi and Akums Drugs, and Below Average management risk is noted for Shilpa Medicare and Strides Pharma. Growth is Below Average across all peers, with the exception of Blue Jet Health and Supriya Lifesci, which have Good growth ratings. Capital Structure is Excellent for Marksans Pharma, Sanofi Consumer, P & G Health Ltd, Blue Jet Health, and Supriya Lifesci, while Good capital structure is noted for Akums Drugs, and Below Average for Viyash Scientifi, Shilpa Medicare, and Strides Pharma.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Viyash Scientifi at 26.25%, while Blue Jet Health has the lowest at -46.94%. P & G Health Ltd's 1-year return of 6.33% is better than Blue Jet Health's but lower than Viyash Scientifi's. Additionally, Blue Jet Health is the only peer with a negative six-month return.

What does P & G Health Ltd do?

Procter & Gamble Health Ltd is a small-cap company in the Pharmaceuticals & Biotechnology industry, formerly known as Merck Limited, with net sales of 370 Cr and a net profit of 95 Cr as of March 2026. The company has a market cap of INR 10,343 Cr and key metrics include a P/E ratio of 32.00 and a dividend yield of 3.30%.

Overview:<BR>Procter & Gamble Health Ltd operates in the Pharmaceuticals & Biotechnology industry and is categorized as a Small Cap company.<BR><BR>History:<BR>The company was incorporated in 1967 as E Merck (India) Limited, later changing its name to Merck Limited on March 27, 2002, and finally to Procter & Gamble Health Limited on May 6, 2019. The latest quarterly results reported net sales and profit for the period ending March 2026.<BR><BR>Financial Snapshot:<BR>- Net Sales: 370 Cr (Quarterly Results - Mar 2026)<BR>- Net Profit: 95 Cr (Quarterly Results - Mar 2026)<BR>- Market Cap: INR 10,343 Cr (Small Cap)<BR><BR>Key Metrics:<BR>- P/E: 32.00<BR>- Industry P/E: 34<BR>- Dividend Yield: 3.30%<BR>- Debt Equity: -0.45<BR>- Return on Equity: 52.75%<BR>- Price to Book: 16.63<BR><BR>Contact Details:<BR>Address: Godrej One 8th Floor, Projshanagar Vikhroli (East) Mumbai Maharashtra : 400079<BR>Tel: 91-22-62109000<BR>Email: investorgrievance.im@pg.com<BR>Website: http://www.pghealthindia.com

Should I buy, sell or hold Procter & Gamble Health Ltd?

Are Procter & Gamble Health Ltd latest results good or bad?

Procter & Gamble Health Ltd's latest Q4 FY26 results are generally positive, with a net profit increase of 54.62% year-on-year, but a slight revenue decline of 0.91% quarter-on-quarter raises concerns about sustaining growth. Overall, strong profitability metrics contrast with challenges in revenue momentum.

Procter & Gamble Health Ltd's latest results for Q4 FY26 can be characterized as generally positive, particularly in terms of profitability metrics. The company reported a net profit of ₹94.60 crores, which is a substantial increase of 54.62% year-on-year and 22.07% quarter-on-quarter. This strong profit growth reflects effective cost management and operational efficiency.<BR><BR>However, there are some concerns regarding revenue growth. Net sales for the quarter were ₹370.45 crores, which represents a slight decline of 0.91% compared to the previous quarter, although it shows a healthy increase of 19.12% year-on-year. This sequential dip in sales may raise questions about the company's ability to sustain revenue momentum.<BR><BR>On the positive side, the operating margin reached a record high of 36.60%, which is a significant improvement from previous quarters. The return on equity (ROE) is also impressive at 47.36%, indicating strong capital efficiency.<BR><BR>In summary, while the profitability metrics are robust and show significant improvement, the slight decline in quarterly sales could be a concern for long-term growth prospects. Overall, the results reflect a mixed picture: strong profitability but challenges in sustaining revenue growth.

How has been the historical performance of P & G Health Ltd?

P & G Health Ltd experienced a decline in net sales and profitability in June 2024, with net sales at 1,151.26 Cr, down from 1,229.62 Cr in June 2023, and profit after tax decreasing to 200.98 Cr from 229.47 Cr. Overall, the company faced challenges with reduced sales, profits, and asset values.

Answer:<BR>The historical performance of P & G Health Ltd shows a fluctuating trend in net sales and profitability over the years. <BR><BR>Breakdown:<BR>In June 2024, P & G Health Ltd reported net sales of 1,151.26 Cr, a decrease from 1,229.62 Cr in June 2023, but an increase from 1,114.41 Cr in June 2022. The total operating income for June 2024 was 1,151.26 Cr, reflecting a similar trend. The company experienced a total expenditure of 845.26 Cr in June 2024, down from 904.94 Cr in June 2023, leading to an operating profit (PBDIT) of 321.63 Cr, which was lower than the 343.07 Cr reported in the previous year. Profit before tax also decreased to 273.32 Cr in June 2024 from 314.20 Cr in June 2023, resulting in a profit after tax of 200.98 Cr, down from 229.47 Cr. The earnings per share (EPS) for June 2024 was 121.07, a decline from 138.23 in June 2023. The company's total assets as of June 2024 were 760.67 Cr, down from 1,075.87 Cr in June 2023, while total liabilities decreased to 760.67 Cr from 1,075.87 Cr. Cash flow from operating activities was 228.00 Cr in June 2024, compared to 236.00 Cr in June 2023, indicating a slight decline in cash generation capabilities. Overall, the financial metrics indicate a challenging year for P & G Health Ltd, with declines in sales, profits, and asset values.

Is P & G Health Ltd technically bullish or bearish?

As of October 6, 2025, the trend is mildly bullish due to daily moving averages and Bollinger Bands, but tempered by mildly bearish weekly MACD and KST indicators, suggesting a cautious bullish outlook.

As of 6 October 2025, the technical trend has changed from bullish to mildly bullish. The current stance is mildly bullish, driven by the daily moving averages indicating mild bullishness and the Bollinger Bands showing a similar trend on both weekly and monthly time frames. However, the weekly MACD and KST are mildly bearish, which tempers the overall bullish sentiment. The Dow Theory also reflects a mildly bearish stance on the weekly chart, while remaining bullish on the monthly. Overall, the mixed signals suggest a cautious bullish outlook.

Who are the top shareholders of the P & G Health Ltd?

The top shareholders of P & G Health Ltd include Procter And Gamble Overseas India B.V. with 51.82%, mutual funds at 10.54%, foreign institutional investors at 6.87%, and Nippon Life India Trustee Ltd as the largest public shareholder at 4.1%. Individual investors collectively own 21.9% of the company.

The top shareholders of P & G Health Ltd include Procter And Gamble Overseas India B.V., which holds the largest stake at 51.82%. The company also has a diverse shareholder base, with mutual funds holding 10.54% across 11 schemes and foreign institutional investors (FIIs) holding 6.87% through 120 different entities. The highest public shareholder is Nippon Life India Trustee Ltd, which holds 4.1%. Additionally, individual investors collectively own 21.9% of the company.

When is the next results date for P & G Health Ltd?

No Upcoming Board Meetings

Has P & G Health Ltd declared dividend?

Procter & Gamble Health Ltd has declared an 800% dividend, amounting to 80 per share, with an ex-date of February 21, 2025. The company has demonstrated strong total returns, particularly over longer periods, with a 44.84% return over the last 5 years.

Procter & Gamble Health Ltd has declared an 800% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 800%<BR>- Amount per share: 80<BR>- Ex-date: 21 Feb 25<BR><BR>Dividend Yield: 2.51%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was 0.61%, the dividend return was 1.43%, resulting in a total return of 2.04%.<BR><BR>Over the past year, the price return stood at 12.45%, with a dividend return of 2.79%, leading to a total return of 15.24%.<BR><BR>For the 2-year period, the price return was 5.24%, the dividend return was 6.69%, culminating in a total return of 11.93%.<BR><BR>In the 3-year span, the price return reached 27.68%, the dividend return was 9.96%, resulting in a total return of 37.64%.<BR><BR>Over the last 4 years, the price return was -4.36%, while the dividend return was 9.08%, leading to a total return of 4.72%.<BR><BR>Finally, in the 5-year period, the price return was 30.81%, the dividend return was 14.03%, resulting in a total return of 44.84%.<BR><BR>Overall, Procter & Gamble Health Ltd has shown a strong dividend declaration alongside positive total returns, particularly in the longer-term periods, indicating a solid performance for investors.